News

The American subsidiary of the German ophthalmic diagnostic device designer announced in a news release that its OCULUS Easyfield VR™ is now available in the US ophthalmic market

A recent study found that despite worldwide reports of ocular inflammatory events being reported after patients received COVID-19 vaccinations, a low amount has been reported in the UK.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

The app is a tool aimed at allowing patients to measure their visual acuity at home by themselves.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Consensus, awareness, and a CVI registry: top priorities of the trans-NIH event

The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

Ophthalmology community continues to rally against efforts to expand the scope of optometrists in multiple states.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

According to the Advanced Research Projects Agency for Health, its program aims to transplant human eyes and reestablish visual connection to the brain.

NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases: who will and will not respond to treatment and what clues are predictive on imaging, at the Retina 2024 meeting in Maui.

In his presentation, Eichenbaum defined gene therapy and described its use in common retinal disease.

The FDA previously granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to ATSN-101 for the treatment of LCA1.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

The kiosk is the first to offer self-service retinal imaging, empowering individuals to capture their own images.

According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.

This trial is a multi-center, open-label safety and tolerability study enrolling 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up.

According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.